Biogen Names Priya Singhal as Executive Vice President, Head of Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Stocks close lower as investors eye Mideast talks, earnings
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Apollo to acquire easyJet for £5.7B in cash deal
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Biogen (BIIB) gains ahead of lecanemab PDUFA
January 6, 2023 7:05 AM ESTBiogen (NASDAQ: BIIB) is gaining 1% in pre-open trade ahead of lecanemab's accelerated approval PDUFA today.
After the close, analysts at RBC Capital noted that Eisai's patient assistance hotline for Leqembi/lecanemab just became active suggesting "increased likelihood an approval."
... MoreRBC Capital on Biogen (BIIB): 'a very favorable stock setup'
January 5, 2023 4:11 PM ESTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $362.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "Sometime between late this morning and now, Eisai's patient assistance hotline for Leqembi/lecanemab just became active, whereas for the last several weeks the phone number (which we obtained via Google search) had not been... More
Biogen's (BIIB) accelerated PDUFA lecanemab approval the likely outcome claim analysts
January 5, 2023 11:50 AM ESTBiogen's (NASDAQ: BIIB) lecanemab's accelerated approval PDUFA is slated for Friday, January 6, and analysts have been weighing in with their view heading into the date.
Jefferies analyst Michael Yee, who has a Buy rating and a $350 price target on Biogen shares, said in a note to clients that the "consensus assumes clean approval, which is reasonable though mostly... More
